Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 3

Pages Range: 273-284

Journal Issue: 4

DOI: 10.1158/2643-3230.BCD-21-0205

Abstract

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Involved external institutions

University of Alabama at Birmingham (UAB) United States (USA) (US) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) Harvard University United States (USA) (US) City of Hope Medical Center United States (USA) (US) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) Icahn School of Medicine at Mount Sinai United States (USA) (US) New York University (NYU) United States (USA) (US) Myeloma Patients Europe AISBL Belgium (BE) University of Miami United States (USA) (US) Mayo Clinic United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Memorial Sloan Kettering Cancer Center United States (USA) (US) Indiana University United States (USA) (US) Erasmus University Medical Center (MC) Netherlands (NL) National University of Singapore (NUS) Singapore (SG) Toulouse Oncopole Cancer University Institute (IUCT-O) / Institut universitaire du cancer de Toulouse Oncopole (IUCT-O) France (FR) Universitätsklinikum Würzburg Germany (DE) Clínica Universidad de Navarra Spain (ES) The Institute of Cancer Research (ICR) United Kingdom (GB) Emory University United States (USA) (US) University Health Network (UHN) Canada (CA) Multiple Myeloma Research Foundation (MMRF) United States (USA) (US) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE)

How to cite

APA:

Davies, F.E., Pawlyn, C., Usmani, S.Z., San-Miguel, J.F., Einsele, H., Boyle, E.M.,... Morgan, G.J. (2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 3(4), 273-284. https://doi.org/10.1158/2643-3230.BCD-21-0205

MLA:

Davies, Faith E., et al. "Perspectives on the Risk-Stratified Treatment of Multiple Myeloma." Blood Cancer Discovery 3.4 (2022): 273-284.

BibTeX: Download